Abstract Iodine-123-iodobenzamide (IBZM) is a specific antagonist of dopamine D2
receptors and usually is used to study neuropsychiatric disorders. It also has a substantial …

Abstract Objectives:(1) To compare scintigraphy using the new dopamine D2 receptor
binding radioligand iodobenzofuran (IBF) versus whole-body positron emission tomography …

N-(2-diethylaminoethyl)-2-iodobenzamide (BZA2) has been singled out as the most
efficacious melanoma scintigraphy imaging agent. Our work was designed to assess the …

Scintigraphy with radiolabeled benzamides was used in melanoma patients. Studies with a
newer benzamide called 123I-epidepride, a high-affinity D2 receptor (D2R) antagonist …

Abstract A new CNS D-2 dopamine receptor imaging agent [125 I] IBZM,(S)-3-[125 I]-iodo-N-
[(1-ethyl-2-pyrro-lidinyl)] methyl-2-hydroxy-6-methoxybenzamide, was prepared by either an …

The cellular uptake of 11 radioiodinated aminoalkyl-iodobenzamides (ABA) was studied
using cultivated murine melanoma cells (B16/C3). All derivatives showed a high uptake (up …

Iodobenzamides labelled with radioactive iodine are undergoing clinical evaluation as
imaging and potential therapeutic agents in malignant melanomas. However, the uptake …

[123I] AIBZM,(S)-5-[123I]-Iodo-N-[(1-ethyl-2-pyrrolidinyl)] methyl-4-amine-2-
methoxybenzamide is a derivative with high affinity for the D2 receptor. Labeling was …

In vivo biodistribution of S-and R-isomers of [125 I] IBZM in rats showed a significant initial
brain uptake (3.20 and 2.67% dose/organ at 2 min, respectively). The wash-out from the …

Biodistribution and Dosimetry of Iodine-123-.IBF: A Potent Radioligand for Imaging the D2
Dopamine Receptor Page 1 in the initiation and maintenance of several neuropsychi atric …